Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after imatinib resistance: a potential diagnostic pitfall.

Zheng S, Huang KE, Jia J, Li X, Tao DY.

Exp Biol Med (Maywood). 2013 Jan;238(1):120-4. doi: 10.1258/ebm.2012.012173.

PMID:
23479771
2.

Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.

Liegl B, Hornick JL, Antonescu CR, Corless CL, Fletcher CD.

Am J Surg Pathol. 2009 Feb;33(2):218-26. doi: 10.1097/PAS.0b013e31817ec2e6.

PMID:
18830121
3.

KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance.

Zheng S, Huang KE, Pan YL, Zhou Y, Pan SD, Li X, Jia J, Zheng XL, Tao DY.

Gastric Cancer. 2015 Oct;18(4):796-802. doi: 10.1007/s10120-014-0414-7. Epub 2014 Aug 15.

PMID:
25182956
4.

Hepatic metastasis with heterologous rhabdomyoblastic differentiation in a patient with gastrointestinal stromal tumor treated with imatinib.

Vij M, Patra S, Rela M.

Indian J Pathol Microbiol. 2013 Jul-Sep;56(3):291-3. doi: 10.4103/0377-4929.120402.

5.

Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall.

Pauwels P, Debiec-Rychter M, Stul M, De Wever I, Van Oosterom AT, Sciot R.

Histopathology. 2005 Jul;47(1):41-7.

PMID:
15982322
6.

[A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].

Miyake M, Takeda Y, Hasuike Y, Kashiwazaki M, Mishima H, Ikenaga M, Mano M, Takada Y, Hirota S, Tsujinaka T.

Gan To Kagaku Ryoho. 2004 Oct;31(11):1791-4. Japanese.

PMID:
15553717
7.

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M, Fletcher CD, Sandau K, McDougall K, Ou WB, Chen CJ, Fletcher JA.

J Clin Oncol. 2006 Oct 10;24(29):4764-74. Epub 2006 Sep 5.

PMID:
16954519
8.

Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.

Agaram NP, Besmer P, Wong GC, Guo T, Socci ND, Maki RG, DeSantis D, Brennan MF, Singer S, DeMatteo RP, Antonescu CR.

Clin Cancer Res. 2007 Jan 1;13(1):170-81.

9.

KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors.

Miranda C, Nucifora M, Molinari F, Conca E, Anania MC, Bordoni A, Saletti P, Mazzucchelli L, Pilotti S, Pierotti MA, Tamborini E, Greco A, Frattini M.

Clin Cancer Res. 2012 Mar 15;18(6):1769-76. doi: 10.1158/1078-0432.CCR-11-2230. Epub 2012 Jan 26.

10.

Gastrointestinal stromal tumor with primary resistance to imatinib and extensive bone metastases.

Tariq Z, Ghose A, Rafiq E, Mohamed I.

Am J Ther. 2011 Sep;18(5):e188-90. doi: 10.1097/MJT.0b013e3181d41eef.

PMID:
20535017
11.

KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.

Loughrey MB, Trivett M, Beshay V, Dobrovic A, Kovalenko S, Murray W, Lade S, Turner H, McArthur GA, Zalcberg J, Waring PM.

Histopathology. 2006 Jul;49(1):52-65.

PMID:
16842246
12.

Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations.

Haller F, Detken S, Schulten HJ, Happel N, Gunawan B, Kuhlgatz J, Füzesi L.

Ann Surg Oncol. 2007 Feb;14(2):526-32. Epub 2006 Dec 2. Review.

PMID:
17139461
13.

Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib.

López RL, del Muro XG.

Anticancer Drugs. 2012 Jun;23 Suppl:S3-6. doi: 10.1097/CAD.0b013e3283559fab. Review.

PMID:
22739667
14.

Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal tumor cells.

Thao le B, Vu HA, Yasuda K, Taniguchi S, Yagasaki F, Taguchi T, Watanabe T, Sato Y.

Cancer Biol Ther. 2009 Apr;8(8):683-8.

PMID:
19417561
15.

Pleomorphic phenotypes of gastrointestinal stromal tumors at metastatic sites with or without imatinib treatment.

Sakamoto K, Sakurai S, Kanda T, Sakuma Y, Hishima T, Hironaka M, Bamba T, Keira Y, Takano Y, Niki T, Hasegawa T, Hirota S.

Cancer Sci. 2010 May;101(5):1270-8. doi: 10.1111/j.1349-7006.2010.01510.x. Epub 2010 Jan 22.

16.

c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.

Miselli FC, Casieri P, Negri T, Orsenigo M, Lagonigro MS, Gronchi A, Fiore M, Casali PG, Bertulli R, Carbone A, Pierotti MA, Tamborini E, Pilotti S.

Clin Cancer Res. 2007 Apr 15;13(8):2369-77.

17.

Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).

Sym SJ, Ryu MH, Lee JL, Chang HM, Kim TW, Kim HC, Kim KH, Yook JH, Kim BS, Kang YK.

J Surg Oncol. 2008 Jul 1;98(1):27-33. doi: 10.1002/jso.21065.

PMID:
18452195
18.

Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.

Yeh CN, Chen TW, Lee HL, Liu YY, Chao TC, Hwang TL, Jan YY, Chen MF.

Ann Surg Oncol. 2007 Mar;14(3):1123-8. Epub 2006 Dec 31.

PMID:
17195905
19.

Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate.

Sciot R, Debiec-Rychter M, Daugaard S, Fisher C, Collin F, van Glabbeke M, Verweij J, Blay JY, Hogendoorn PC; EORTC Soft Tissue and Bone Sarcoma Group; Italian Sarcoma Group; Australasian Trials Group.

Eur J Cancer. 2008 Sep;44(13):1855-60. doi: 10.1016/j.ejca.2008.06.003. Epub 2008 Jul 22.

PMID:
18653326
20.

Gastrointestinal stromal tumors (GIST): a single center experience.

Kostka R, Gürlich R, Koldová L.

Acta Chir Belg. 2012 Jan;112(1):33-9.

PMID:
22442907

Supplemental Content

Support Center